DrugPatentWatch Database Preview
KRINTAFEL Drug Profile
When do Krintafel patents expire, and what generic alternatives are available?
Krintafel is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in KRINTAFEL is tafenoquine succinate. Two suppliers are listed for this compound. Additional details are available on the tafenoquine succinate profile page.
Summary for KRINTAFEL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 12 |
| Patent Applications: | 128 |
| Drug Prices: | Drug price information for KRINTAFEL |
| DailyMed Link: | KRINTAFEL at DailyMed |
Synonyms for KRINTAFEL
| (+/-)-8-[(4-amino-1-methylbutyl)amino]-2,6-dimethoxy-4-methyl-5-(3-trifluoromethylphenoxy) quinoline |
| (4-Amino-1-methylbutyl){2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy](8-quinolyl)}amine |
| (R)-N3-(2,6-Dimethoxy-4-methyl-5-(3-trifluoromethyl)phenoxy)quinolin-8-yl)pentane-1,4-diamine |
| (RS)-N(sup 3)-(2,6-Dimethoxy-4-methyl-5-(3-trifluoro-methylphenoxy)quinolin-8-yl)pentane-1,4-diamine |
| 1,4-Pentanediamine, N4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)-8-quinolinyl)- |
| 1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]- |
| 106635-80-7 |
| 4-N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine |
| AC1L3GZN |
| Arakoda |
| C24H28F3N3O3 |
| CHEBI:141487 |
| CHEMBL298470 |
| CS-0042381 |
| D10490 |
| Etaquine |
| GTPL9722 |
| HY-111529 |
| LBHLFPGPEGDCJG-UHFFFAOYSA-N |
| LS-172012 |
| N(4)-(2,6-Dimethoxy-4-methyl-5-((3-trifluoromethyl)phenoxy)-8-quinolinyl)-1,4-pentanediamine |
| N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine |
| N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolyl]pentane-1,4-diamine |
| SB-252263 |
| SB-252263-AAB |
| SB-252263AAB |
| SB16555 |
| SCHEMBL347388 |
| Tafenoquine |
| Tafenoquine (USAN) |
| Tafenoquine [INN:BAN] |
| Tafenoquine [USAN:INN:BAN] |
| WR 238605 |
| WR-238605 |
| WR238605 |
US Patents and Regulatory Information for KRINTAFEL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | KRINTAFEL | tafenoquine succinate | TABLET;ORAL | 210795-001 | Jul 20, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Glaxosmithkline | KRINTAFEL | tafenoquine succinate | TABLET;ORAL | 210795-001 | Jul 20, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
